Intrathecal dermorphine in postoperative analgesia

Area of Science:

• Anesthesiology and Pain Management
• Pharmacology

Background:

• Postoperative pain management is crucial for patient recovery.
• Intrathecal drug delivery offers targeted analgesia.
• Comparing novel and established analgesics is essential for optimizing pain control.

Purpose of the Study:

• To compare the efficacy of intrathecal dermorphine, intrathecal morphine, and intramuscular pentazocine for postoperative pain relief.
• To evaluate the duration of analgesia and impact on hospital stay.
• To assess the incidence of side effects associated with each analgesic regimen.

Main Methods:

• Prospective randomized double-blind study involving 150 patients undergoing elective surgery.
• Administration of intrathecal morphine (500 mcg), intrathecal dermorphine (20 mcg), or intramuscular pentazocine (30 mg).
• Assessment of pain relief, duration of analgesia, hospital stay, and side effects.

Main Results:

• Intrathecal dermorphine demonstrated significantly longer-lasting analgesia (43.41 hrs) compared to intrathecal morphine (34.45 hrs) and pentazocine (10.79 hrs).
• Patients receiving intrathecal dermorphine or morphine had significantly shorter mean postoperative hospital stays (5.6 and 6.3 days, respectively) than the pentazocine group (8.7 days).
• No significant differences in side effects (urinary retention, vomiting, headache) were observed among the groups.

Conclusions:

• Intrathecal dermorphine is a highly effective analgesic for postoperative pain, offering prolonged relief and reduced hospital stay.
• Intrathecal dermorphine presents a promising alternative to intrathecal morphine and conventional pentazocine therapy.
• The safety profile of intrathecal dermorphine appears comparable to other tested analgesics.